OTCPK:IMMP.F

Stock Analysis Report

Executive Summary

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Share Price & News

How has ImmuPharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

IMMP.F

-0.1%

US Pharmaceuticals

1.0%

US Market


1 Year Return

n/a

IMMP.F

-6.2%

US Pharmaceuticals

6.7%

US Market

Return vs Industry: Insufficient data to determine how IMMP.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how IMMP.F performed against the US Market.


Share holder returns

IMMP.FIndustryMarket
7 Day0%-0.1%1.0%
30 Day0%-0.5%-1.8%
90 Day0%-2.6%-1.8%
1 Yearn/a-3.9%-6.2%9.1%6.7%
3 Yearn/a17.4%9.1%46.1%36.6%
5 Yearn/a28.0%14.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is ImmuPharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ImmuPharma undervalued based on future cash flows and its price relative to the stock market?

1.95x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate IMMP.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate IMMP.F's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: IMMP.F is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: IMMP.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate IMMP.F's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: IMMP.F is good value based on its PB Ratio (2x) compared to the US Pharmaceuticals industry average (2.8x).


Next Steps

Future Growth

How is ImmuPharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

11.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: IMMP.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMMP.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMMP.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMMP.F's revenue (30.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: IMMP.F's revenue (30.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if IMMP.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ImmuPharma performed over the past 5 years?

-18.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IMMP.F is unprofitable, and losses have increased over the past 5 years at a rate of -18.7% per year.

Accelerating Growth: Unable to compare IMMP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMMP.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: IMMP.F has a negative Return on Equity (-94.44%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IMMP.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IMMP.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is ImmuPharma's financial position?


Financial Position Analysis

Short Term Liabilities: IMMP.F's short term assets (£4.4M) exceeds its short term liabilities (£541.4K)

Long Term Liabilities: IMMP.F has no long term liabilities


Debt to Equity History and Analysis

Debt Level: IMMP.F's debt to equity ratio (1.3%) is considered satisfactory

Reducing Debt: IMMP.F's debt to equity ratio has reduced from 91.8% to 1.3% over the past 5 years.


Balance Sheet

Inventory Level: IMMP.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: IMMP.F's debt is covered by short term assets (assets are 44.888000x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMMP.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IMMP.F has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.5% each year.


Next Steps

Dividend

What is ImmuPharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.3%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate IMMP.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IMMP.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IMMP.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMMP.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMMP.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of ImmuPharma's salary, the management and board of directors tenure and is there insider trading?

6.3yrs

Average board tenure


CEO

Dimitri Dimitriou (57yo)

0yrs

Tenure

UK£305,114

Compensation

Mr. Dimitri F. Dimitriou, M.Sc, serves as the Co-Founder and Chief Executive Officer of Immupharma PLC. Mr. Dimitriou serves as Commercial Advisor and Chief Business Officer and commercial advisorof Unibio ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Dimitri's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Dimitri's compensation has been consistent with company performance over the past year.


Board Age and Tenure

6.3yrs

Average Tenure

68yo

Average Age

Experienced Board: IMMP.F's board of directors are considered experienced (6.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Dimitri Dimitriou (57yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: UK£305.11k
  • D. Henri Zimmer (71yo)

    Co-Founder

    • Tenure: 13.7yrs
    • Compensation: UK£498.50k
  • Jean-Marie Geiger

    Head of Clinical Development

    • Tenure: 0yrs
  • Tracy Weimar

    VP of Operations & Finance and Company Secretary

    • Tenure: 12.7yrs
  • Lisa Baderoon

    Head of Investor Relations

    • Tenure: 7.7yrs

Board Members

  • Dimitri Dimitriou (57yo)

    Co-Founder

    • Tenure: 0yrs
    • Compensation: UK£305.11k
  • Stéphane Robert Méry

    Non-Executive Director

    • Tenure: 4.5yrs
    • Compensation: UK£45.00k
  • Tim McCarthy (62yo)

    Non-Executive Chairman

    • Tenure: 4.1yrs
    • Compensation: UK£260.00k
  • Lee Simon (68yo)

    Member of Scientific Advisory Board

    • Tenure: 6.3yrs
  • D. Henri Zimmer (71yo)

    Co-Founder

    • Tenure: 13.7yrs
    • Compensation: UK£498.50k
  • Vibeke Strand

    Member of Scientific Advisory Board

    • Tenure: 6.3yrs
  • Franco Di Muzio (81yo)

    Senior Non-Executive Director

    • Tenure: 0yrs
    • Compensation: UK£55.05k
  • David Isenberg

    Member of Scientific Advisory Board

    • Tenure: 6.3yrs
  • Dan Wallace

    Member of Scientific Advisory Board

    • Tenure: 6.3yrs
  • Cees Kallenberg

    Member of Scientific Advisory Board

    • Tenure: 6.3yrs

Company Information

ImmuPharma plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImmuPharma plc
  • Ticker: IMMP.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£17.489m
  • Listing Market Cap: UK£21.521m
  • Shares outstanding: 167.36m
  • Website: https://www.immupharma.com

Number of Employees


Location

  • ImmuPharma plc
  • 50 Broadway
  • Westminster
  • London
  • Greater London
  • SW1H 0RG
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMMAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPFeb 2006
IMMP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2006
25IDB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 2006

Biography

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company’s lead product candidate is the Lupuzor, which has complete ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/07 02:49
End of Day Share Price2019/07/09 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)